share_log
Breakings ·  Dec 3 20:30
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of Aro-Alk7 for the Treatment of Obesity
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment